An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide “substantial evidence” of efficacy.
An FDA expert panel has recommended against the approval of Capricor Therapeutics' treatment for Duchenne muscular dystrophy. The decision follows a contentious regulatory review process that has raised significant concerns among stakeholders.